Evaluation of titers of antibodies against peptides of subunits NR1 and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies.
Patients with anti-thyroid antibodies (ATAs) are reported to exhibit atypical psychiatric symptoms. We have been reported that psychiatric patients with ATAs (PPATs) have anti-N-methyl-Daspartate (NMDA) type glutamate receptor (NMDA-R) antibodies by western blot analysis. NMDA-R forms a tetramer with the subunit glutamate receptors (GluR) GluRζ1 (NR1) and GluRε2 (NR2B). However, the possible etiological role of anti-NR1 and anti-NR2B antibodies in PPATs remains unclear.



First, we evaluated titers of anti-NR1 and anti-NR2B antibodies in PPATs by enzyme-linked immunosorbent assay (ELISA). Next, we investigated the relationships among titers of anti-NR1 and anti-NR2B antibodies. Finally, we investigated the relationship between anti-NMDAR antibodies and the psychiatric symptoms in the PPATs.



There was a strong correlation between anti-NR1 antibodies and anti-NR2B antibodies in the CSF, and some correlation between these antibodies in the serum. High titers of anti-NR2B antibodies in the serum of PPATs contributed to development of hallucinations and high titers of anti-NR1 antibodies in the serum contributed to development of anxiety by logistic regression.



High titers of anti-NR2B antibodies in the serum is a risk factor for hallucinations and high titers of anti-NR1 antibodies in the serum is a risk factor for anxiety in PPATs.
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan.
Takahiro
T
Ikura
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan. Electronic address: oxm08@yahoo.co.jp.
Omi
O
Katsuse
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan.
Yuhei
Y
Chiba
Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Aoi-ku, Shizuoka City, Shizuoka 420-8688, Japan.
Yukitoshi
Y
Takahashi
Department sleep of medicine, Nagoya University Graduate School of Medicine, 65 Turumaichou, Shouwa-ku, Nagoya City, Aiti 466-8550, Japan.
Hiroshige
H
Fujishiro
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan.
Ayuko
A
Kamada
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan.
Tomoyuki
T
Saito
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan.
Yoshio
Y
Hirayasu
D001007:Anxiety / Q000150:complications / Q000276:immunology; D001323:Autoantibodies / Q000097:blood* / Q000134:cerebrospinal fluid*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006212:Hallucinations / Q000150:complications / Q000276:immunology; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000276:immunology*; D008875:Middle Aged; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology*; D013959:Thyroid Diseases / Q000150:complications / Q000276:immunology
D001323:Autoantibodies; C409466:NR1 NMDA receptor; C121001:NR2B NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate
Anti-N-methyl-d-aspartate type glutamate receptor; Anti-thyroid antibodies; Enzyme-linked immunosorbent assay; Hashimoto’s encephalopathy; NR1; NR2B